Three different studies were conducted to determine the safety aspects of VEDICINALS® 9 prior to human clinical studies and these studies involved high dose oral ingestion of VEDICINALS® 9 by Sprague Dawley Rats.
In the first two which involved acute and sub-acute toxicity testing without single mortality over periods of 14 and 28 days, the results showed no severe adverse clinical symptoms/or mortalities in the test subjects.
The study showed that even with high dose toxicity test of VEDICINALS® 9, (As Class 5, > 5000 mg/kg) there were no reported adverse events or conditions.
In the Myocardial infarction study, the results were remarkable in the sense that not only were there no adverse events or conditions reported from high dose application, there was actually data showing that VEDICINALS® 9 provided cardio protective benefits including significant protection of heart muscle tissues, blood vessels and the cardiovascular system.
Acute and Sub Acute toxicity testing without single mortality.
- 28 days repeat dose toxicity trial on 72 animals. Results: successful forVEDICINALS® 9 without severe adverse clinical symptoms/or mortalities.
- High dose toxicity test ofVEDICINALS® 9, as Class 5, > 5000 mg/kg . Without seve adverse symptoms/or mortalities.
Myocardial infarction trial: Showing significant protection of Heart muscle tissues, blood vessels and the cardiovascular system. All (also high dosage) animal trials were conducted without a single mortality outcome.